The programme allows for new or existing clients to increase the time or bandwidth they use by multiples of up to 10 to meet needs as they arise. The new program is available as an on-premise, hybrid or cloud-based solution.
In recent weeks, many organisations have exponentially increased their demand for video communication platforms.
Vidyo's track record of supporting large health organisations, as well as major financial corporations, government agencies and educational institutions, positions it as an ideal solution for rapidly evolving contingency plans.
Specifically, the Vidyo Telehealth solution enables clinics and hospitals to protect front-line staff and patients by supporting self-isolation and quarantine scenarios, and ensures clinicians, nurses and physicians can provide remote diagnoses and treatments, often with existing technology.
Vidyo enriches people's lives by embedding real-time video into digital communications in the moments that matter most.
Millions of people around the world connect visually every day through Vidyo's secure, scalable technology and cloud-based services.
Its patented platform integrates with virtually any application environment, network and device to deliver the highest quality experiences that strengthen teams, build trust, solidify relationships, and improve quality of life.
Microbot Medical secures first Japanese patent for Liberty robotic system following FDA clearance
Polarean Imaging signs new supply agreementwith UVA Health for clinical Xenon MRI
Femasys partners with Kebomed to expand FemBloc permanent birth control in France and Benelux
Implantica receives positive FDA feedback on final RefluxStop PMA submission
Tempus secures FDA clearance for RNA-based xR IVD diagnostic device
Shoulder Innovations expands I-Series portfolio with launch of InSet 70 Humeral Stem
GSK commits USD30bn to US R&D and manufacturing expansion
ArtPlayer Promotes Elderly Wellbeing with Digital Signage and Streaming Art in Finnish Care Homes
Implantica produces 10,000 RefluxStop units ahead of planned US launch
Elute partners Spartan Medical
Saol Therapeutics receives US FDA Complete Response Letter for SL1009 (DCA) in PDCD
Abbott's Navitor TAVI system granted CE Mark for expanded indication
PharmaResearch names VIVACY as European distribution partner for Rejuran
Airiver medical receives FDA approval for central airway stenosis trial